Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Adenosine A2A Receptor-Targeted Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ADORA2A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Protein) | ADORA2A N-terminal ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1 EU/ug. Sequence Verified. HEK293 Expressed. |
View ADORA2A Products |
| Antigen (Lentivirus) | ADORA2A Lentivirus Premade Particles Optimized for GPCR stable cell line generation. Preserves complex multipass conformation. |
View ADORA2A Products |
| Gene Delivery | ADORA2A Promise-ORF Full-length ORF clone for custom expression. High purity (>95%), Endotoxin Controlled. |
View ADORA2A Products |
| Benchmark Control | Anti-ADORA2A Reference Antibody (Clone 7F6-SS) / Small Molecule Antagonists Reference controls for screening and pathway validation. |
View ADORA2A Products |
| Validator | ADORA2A siRNA Set For functional knockdown verification and pathway analysis. |
View ADORA2A Products |
| Related Target A | NT5E (CD73) Upstream ecto-enzyme in the adenosine pathway; highly synergistic for combination therapies in solid tumors. |
View NT5E Products |
| Related Target B | ENTPD1 (CD39) Upstream modulator converting ATP to AMP; critical for targeting the immunosuppressive tumor microenvironment (TME). |
View ENTPD1 Products |
| Related Target C | ADORA2B Receptor homolog required for selectivity counter-screening to prevent off-target effects. |
View ADORA2B Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex GPCR Conformation | Lentivirus delivery system ensures native multipass membrane folding and functional surface expression in HEK293/CHO host cells. |
| Receptor Subtype Selectivity (A1/A2B/A3) | Comprehensive lentiviral panels for all Adenosine receptor homologs, Sequence Verified for precise off-target screening. |
| Lack of Controls | Clinical Benchmark antibodies and compounds available for robust assay calibration. |
| False Positives in Screening | Validated siRNA included for specificity checks and target-dependency confirmation. |
Live ADORA2A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ADORA2A therapeutics is intensifying, with major players shifting focus from neurological applications (like Parkinson's disease) to highly targeted small molecule antagonists and emerging biologicals in Immuno-Oncology. As the tumor microenvironment (TME) relies on adenosine signaling to suppress immune responses, ADORA2A has become a critical checkpoint. As first-generation therapies reach the clinic, the next wave of R&D is targeting dual-antagonism (e.g., ADORA2A/ADORA2B) and strategic combinations with PD-1/PD-L1 inhibitors to overcome immune evasion.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonists | Arcus Biosciences, Corvus Pharmaceuticals, Kyowa Kirin | Solid Tumors, Parkinson's Disease | Receptor Selectivity (Need ADORA1, 2A, 2B, 3 stable cell lines via Lentivirus) |
| Monoclonal Antibodies | Early-stage biotech | Immuno-oncology | Binding & Internalization Assay (Need natively folded GPCRs on cell surfaces) |
| Combination Therapies (w/ Checkpoints) | AstraZeneca, Merck | Refractory Cancers (TME) | Functional Cellular Assays (cAMP accumulation/calcium flux on engineered cells) |
Key Genetic Variations in ADORA2A
The ADORA2A gene harbors several naturally occurring single-nucleotide polymorphisms (SNPs) that can influence receptor function, drug response, and disease susceptibility. The following mutations are documented in UniProt (P29274) and dbSNP:
| Variant | dbSNP ID | Annotation | Evidence |
|---|---|---|---|
| rs4530 | rs4530 | Missense variant in coding region | UniProt VAR_011835 |
| rs4990 | rs4990 | Missense variant in coding region | UniProt VAR_011836 |
| rs1277013918 | rs1277013918 | Variant in coding region | UniProt VAR_003451 |
These genetic variants may impact receptor expression, ligand binding, or downstream signaling. Understanding patient genotype could inform personalized therapy selection, especially in the context of adenosine-targeted immunotherapies.